Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain

Keyphrases

• Patients with Cancer 100%
• Morphine 100%
• Morphine Treatment 100%
• Chronic Non-cancer Pain 100%
• Morphine-6-glucuronide 66%
• Cancer Patients 50%
• Non-cancer 50%
• Morphine-3-glucuronide 41%
• Slow-release Oral Morphine 41%
• Treatment Duration 25%
• Daily Dose 25%
• Dryness 25%
• Glucuronidation 16%
• Stable Dose 16%
• Blood Samples 8%
• Antidepressants 8%
• Adverse Effects 8%
• Plasma Concentration 8%
• Analgesic Effect 8%
• Pharmacokinetics 8%
• Sedation 8%
• Pain Score 8%
• Pharmacodynamics 8%
• Pain Patients 8%
• Nonmalignant 8%
• High-performance Liquid Chromatography 8%
• Metabolite Ratios 8%
• Extended Period 8%
• Treatment Dose 8%
• M-ratio 8%
• Oral Sustained Release 8%
• Treatment Period 8%
• Morphine Equivalent Dose 8%
• Increasing Dose 8%
• Patients with Chronic Pain 8%
• Group-making 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Cancer Pain 100%
• Morphine 100%
• Morphine 6 Glucuronide 40%
• Sustained Release 25%
• Morphine 3 Glucuronide 25%
• Side Effect 10%
• Antidepressant 5%
• Analgesic Agent 5%
• Pharmacodynamics 5%
• Chronic Pain 5%
• High Performance Liquid Chromatography 5%
• Pharmacokinetics 5%
• Adverse Effect 5%